Shengxiang Biology (688289.SH) announced that the company intends to partner with the relevant party Hunan Xiangjiang Shengxiang Biological Industry Fund...
Zhitong Finance App News, Shengxiang Biotech (688289.SH) announced that the company plans to jointly invest in the joint venture Hunan Shengwei Sumin Biotechnology Co., Ltd. (“Hunan Shengwei”) with the related party Hunan Xiangjiang Shengxiang Biological Industry Fund Partnership (“Industrial Fund”), of which the company's investment amount is RMB 53.33 million. At the same time, the company plans to transfer 21.69% of the shares in the participating company First Light Diagnostics, Inc. (“First Light”) to a wholly-owned subsidiary under the joint venture, with a transfer consideration of US$2,215,800.
According to reports, First Light's rapid drug sensitivity testing platform can directly detect original samples, significantly reducing the waiting time for diagnosis and treatment, helping to select appropriate antibiotic treatments in a timely manner, reduce inappropriate antibiotic use, and is expected to become a more cost-effective rapid drug sensitivity clinical solution, and forms a product portfolio with commercial synergy effects with the company's pathogen identification products, complementing the company's main business, thus helping the company create a more comprehensive solution for infectious disease diagnosis in a full-scenario manner, further improving the layout of the entire ecological industry chain.